| PERIOD ENDING | 30-Sep-09 | 30-Jun-09 | 31-Mar-09 | 31-Dec-08 | | Total Revenue | 786,390 | 852,457 | 809,059 | 856,689 | | Cost of Revenue | 161,593 | 176,081 | 187,569 | 209,945 | | | Gross Profit |
-
| 676,376 | 621,490 | 646,744 | | | Operating Expenses | | Research Development |
-
|
-
|
-
|
-
| | Selling General and Administrative | 384,102 | 318,634 | 349,921 | 370,907 | | Non Recurring | (23,508) | 27,739 | 2,602,713 |
-
| | Others | 492,131 | 430,824 | 308,972 | 868,877 | | | | Total Operating Expenses |
-
|
-
|
-
|
-
| | | | Operating Income or Loss |
-
| (100,821) | (2,640,116) | (593,040) | | | Income from Continuing Operations | | Total Other Income/Expenses Net |
-
|
-
|
-
|
-
| | Earnings Before Interest And Taxes | (227,928) | (100,821) | (2,640,116) | (593,040) | | Interest Expense | 29,434 | 37,024 | 44,883 | 76,198 | | Income Before Tax | (257,362) | (137,845) | (2,684,999) | (669,238) | | Income Tax Expense | (91,172) | (12,750) | (251,792) | (251,949) | | Minority Interest |
-
|
-
|
-
|
-
| | | | Net Income From Continuing Ops | (166,190) | (125,095) | (2,433,207) | (417,289) | | | Non-recurring Events | | Discontinued Operations |
-
|
-
|
-
|
-
| | Extraordinary Items |
-
|
-
|
-
|
-
| | Effect Of Accounting Changes |
-
|
-
|
-
|
-
| | Other Items |
-
|
-
|
-
|
-
| | | | Net Income | (166,190) | (125,095) | (2,433,207) | (417,289) | | Preferred Stock And Other Adjustments | (29,223) | (57,451) | (58,793) | (23,158) | | | Net Income Applicable To Common Shares | ($195,413) | ($182,546) | ($2,492,000) | ($440,447) |
|
0.03% Nasdaq 0.00%
Income Statement
